Empagliflozin resources and events banner

Downloadable resource

Empagliflozin patient booklets

Patient friendly booklets for indications that supports treatment adherence by helping Empagliflozin patients better understand their diagnosis, therapy, and long term management needs.

Downloadable resource

Empagliflozin CRM patient booklet

Support patients starting their treatment on Empagliflozin with clear guidance on what to expect and how to manage therapy.

Download now Opens in new tab

Alternative languages are available here

Downloadable resource

Empagliflozin Initiation & Management guide for T2D, CHF and CKD

Practical guidance to support initiation and ongoing management across T2D, CKD and heart failure.

Download now Opens in new tab

Downloadable resource

The role of pharmacists in CKD care

An evidence-based overview of how pharmacists can support early identification, testing and management of CKD.

Download now Opens in new tab

Downloadable resource

CKD management checklist for pharmacists

A practical checklist to support testing, coding and management of people with CKD in primary care.

Download now Opens in new tab

Watch now

Video

Identifying and managing CKD in primary care

Watch Dr Sarah Jarvis and Professor Smeeta Sinha discuss diagnosis and management of chronic kidney disease

Watch now

Video

Cardio Renal Metabolic Conditions and EMPA-REG

Watch Dr Janaka Karalliedde discuss cardio renal metabolic conditions and the EMPA-REG OUTCOME trial

Watch now

Video

The EMPA-REG OUTCOME Trial: Participants and CV mortality outcome

Watch Dr Jarvis and Dr Javaid discuss the EMPA-REG OUTCOME trial: participants and CV mortality outcome

Watch now

PC-GB-112293 | April 2026

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Disclaimer

The content on this website is in relation to adult patients.

Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.

Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing Empagliflozin.

Empagliflozin UK Summary of Product Characteristics (SmPC).

Indications

Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

as monotherapy when metformin is considered inappropriate due to intolerance
in addition to other medicinal products for the treatment of diabetes¹

Empagliflozin is indicated in adults for the treatment of chronic kidney disease.¹

Empagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure.¹

PC-GB-112290 | April 2026